Caliway Biopharmaceuticals Company Description

Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation.

The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum’s disease, as well as for cellulite treatment.

It is also developing CBA-539, which is in preclinical stage for central obesity, hyperpigmentation, and skin aging, as well as offers dietary supplements.

The company was incorporated in 2012 and is based in New Taipei City, Taiwan.

Caliway Biopharmaceuticals Co., Ltd.

Country	Taiwan
Founded	2012
Industry	Biotechnology
Sector	Healthcare
CEO	Yufang Ling

Contact Details

Address: No.99, Xintai 5th Road New Taipei City, 221 Taiwan
Phone	886 2 2697 1355
Website	caliway.com.tw

Stock Details

Ticker Symbol	6919
Exchange	Taiwan Stock Exchange
Fiscal Year	January - December
Reporting Currency	TWD
SIC Code	2834

Key Executives

Name	Position
Yufang Ling	Chief Executive Officer and Research & Development Chief
Lu-hui Hsu	Chief Strategy Officer and Chairman